Methylone and Monoamine Transporters: Correlation with Toxicity

Chiharu Sogawa, Norio Sogawa, Kazumi Ohyama, Ruri Kikura-Hanajiri, Yukihiro Goda, Ichiro Sora and Shigeo Kitayama*

*Department of Dental Pharmacology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8525, Japan; IR Research Center, Okayama University Dental School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8525, Japan; Division of Pharmacognosy, Phytochemistry and Narcotics, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan; Department of Biological Psychiatry, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan

Abstract: Methylone (2-methylamino-1-[3,4-methylenedioxyphenyl]propane-1-one) is a synthetic hallucinogenic amphetamine analog, like MDMA (3,4-methylenedioxyamphetamine), considered to act on monoaminergic systems. However, the psychopharmacological profile of its cytotoxicity as a consequence of monoaminergic deficits remains unclear. We examined here the effects of methylone on the transporters for dopamine (DAT), norepinephrine (NET), and serotonin (SERT), using a heterologous expression system in CHO cells, in association with its cytotoxicity. Methylone inhibited the activities of DAT, NET, and SERT, but not GABA transporter-1 (GAT1), in a concentration-dependent fashion with a rank order of NET > DAT > SERT. Methylone was less effective at inhibiting DAT and NET, but more effective against SERT, than was methamphetamine. Methylone alone was not toxic to cells except at high concentrations, but in combination with methamphetamine had a synergistic effect in CHO cells expressing the monoamine transporters but not in control CHO cells or cells expressing GAT1. The ability of methylone to inhibit monoamine transporter function, probably by acting as a transportable substrate, underlies the synergistic effect of methylone and methamphetamine.

Keywords: Methylone, neurotransmitter transporter, uptake, cocaine, methamphetamine, MDMA.

INTRODUCTION

Various illegal and/or restricted “designer drugs” have been created by modifying amphetamines. Methylone (2-methylamino-1-[3,4-methylenedioxyphenyl]propane-1-one) is one such synthetic hallucinogenic amphetamine analogue, which resembles MDMA (3,4-methylenedioxyamphetamine) but differs structurally by the presence of a ketone at the benzylic position [1, 2]. This compound has been newly placed under legal control as a drug of abuse in Japan [3].

Because of its structural similarity to MDMA, methylone is thought to act on monoaminergic systems. A behavioral study by Dal Cason et al. [4] found that methylone substituted for MDMA in rats trained to discriminate MDMA from saline. In studies of its pharmacology in vitro methylone was threefold less potent than MDMA at inhibiting platelet serotonin transporter (SERT) and as potent as MDMA in inhibiting transporters for dopamine (DAT) and norepinephrine (NET), but only weakly inhibited the vesicular monoamine transporter [5, 6]. However, there have been few pharmacological investigations of methylone in animal models, or studies about its mechanism of action.

In addition, the cytotoxicity of MDMA is considered a consequence of monoaminergic deficits through the drug’s effects on the plasmalemmmal and vesicular monoamine transporters [7, 8]. Again, methylone may resemble MDMA in cytotoxic profiles. However, Nakagawa et al. [9] reported that methylone did not exhibit cytotoxic effects on isolated rat hepatocytes in contrast to MDMA and its analogues. The possibility cannot be excluded that methylone is cytotoxic in some circumstances, since Nagai et al. [6] observed that like MDMA, it reduced mitochondrial membrane potential.

Recently, we examined the effects of 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), known as Foxy, on monoamine neurotransmitter transporters, including DAT, NET and SERT, using a heterologous expression system in COS-7 cells and rat brain synaptosomes, in association with its cytotoxicity [10]. In the present study, we used the same strategy to evaluate the relationship between the effects of methylone and methamphetamine on monoamine transporters and cell toxicity.

The results indicated an ability of methylone to inhibit monoamine transporter function, and cause damage synergistically with methamphetamine in cells heterologously expressing monoamine transporters, suggesting that the transport of these drugs underlies their cytotoxicity.

MATERIALS AND METHODS

Materials

Methylone was synthesized at the Division of Pharmacognosy, Phytochemistry and Narcotics, National Institute of
Health Sciences (Tokyo, Japan). Its structure and purity were confirmed by melting point (degradation, 225°C), TLC, GC-MS and $^1$H-NMR analyses [11]. Other chemicals used were purchased from commercial sources. $[^1]$H]Dopamine (DA) (1.29 TBq/mmol), $[^1]$H]serotonin (5-HT) (1.04 TBq/mmol), and $[^1]$H]GABA (1.2 TBq/mmol) were obtained from PerkinElmer Life Science, Inc. (Boston, MA, USA), and $[^1]$H]norepinephrine (NE) (1.18 TBq/mmol) from GE healthcare Bioscience, Inc. (Buckinghamshire, UK).

Cell Culture and Expression

Chinese hamster ovary (CHO) cells were cultured at 37°C under 5 % CO$_2$ / 95 % air in Minimum Essential Medium-alpha (MEM) supplemented with 10 % fetal calf serum, 100 units/ml penicillin G, 100 $\mu$g/ml streptomycin, 2 mM CaCl$_2$, 1.4 mM MgSO$_4$, 1.2 mM KH$_2$PO$_4$, 5 mM glucose, and 0.25 $\mu$g/ml fungisone.

For the preparation of cell lines stably expressing transporters, CHO cells at subconfluence were transfected with cDNA of rat DAT (rDAT), NET (rNET), or SERT (rSERT), or mouse GABA transporter-1 (mGAT1) using FuGENE6 transfection reagent (Roche Diagnostics, Mannheim, Germany) according to the manufacturer’s directions. The cells were then diluted sequentially, seeded in 96-well plates, and selected using G418. The cell lines were confirmed to stably express the transporters based on the uptake of each tritium-labeled ligand, and designated CHO/rDAT, CHO/rNET, CHO/rSERT and CHO/mGAT1, respectively.

Uptake and Release Assay

The uptake assay using radio-labeled ligands was performed, as described previously [10, 12]. Cells were washed three times with an oxygenated Krebs Ringer HEPES-buffered solution (KRH; 125 mM NaCl, 5.2 mM KCl, 1.2 mM CaCl$_2$, 1.4 mM MgSO$_4$, 1.2 mM KH$_2$PO$_4$, 5 mM glucose, and 20 mM HEPES, pH 7.3) and incubated for 10 min at 37°C with 10 nM of $[^3]$H]DA or other radio-labeled ligand. Nonspecific uptake was determined in mock-transfected cells and also in each plate in the presence of 100 $\mu$M cocaine for monoamine and 1 $\mu$M nipecotic acid for GABA. Data were analyzed using Eadie-Hofstee plots with Prism 5 (GraphPad Software, Inc., San Diego, CA). Statistical analyses were performed using the unpaired Student’s t-test.

Reverse transport (release) was analyzed, as described [10]. Cells loaded with $[^3]$H]substrate were incubated with or without the drug under investigation at 37°C for 2 min, and separated from the incubation solution. The radioactivity retained in the cells and also in the separated solution was measured by liquid scintillation counting. Statistical tests were performed using an analysis of variance (Kruskal-Wallis test) with pairwise comparisons using Dunn’s multiple comparison test.

Cell Toxicity Assay

The amount of lactate dehydrogenase (LDH) released into the culture medium was measured for the evaluation of methylone’s toxicity, as described previously [12] with some modifications. Briefly, cells cultured in 96-well culture plates were washed and incubated without phenol red in α-MEM supplemented with 1% BSA and different concentrations of methylone and/or methamphetamine for 24 h. The amount of LDH released into the medium was measured colorimetrically (Wako, Tokyo, Japan). Statistical analyses were performed using the Kruskal-Wallis test and Dunn’s multiple comparison test.

RESULTS

Effects of Methylone on the Uptake of Substrate in CHO Cells Stably Expressing Monoamine and GABA Transporters

The effect of methylone on the transport of monoamines was examined in CHO cells stably expressing the rat monoamine transporters, rDAT, rNET and rSERT, in comparison with that on the mouse GABA transporter, mGAT1. Simultaneous incubation with $[^3]$H]DA, $[^3]$H]NE, or $[^3]$H]5HT and methylone caused a decrease in the uptake of $[^3]$H]substrate in a concentration-dependent fashion, although the effects differed between transporters in contrast to the effects of methamphetamine (Fig. 1). The rank order of the transporters in terms of the potency with which they were inhibited by methylone was NET > DAT >> SERT (Fig. 1 and Table 1). Methylone inhibited SERT more, DAT and NET less, than methamphetamine. However, it had no effect on GAT transport activity at concentrations up to 1 mM (Fig. 1), while nipecotic acid, an inhibitor of neuronal GABA transporter such as GAT-1, inhibited $[^3]$H]GABA uptake in a concentration-dependent manner (data not shown).

![Graph](image)

Fig. (1). Effects of methylone on the uptake of substrates in CHO cells stably expressing monoamine and GABA transporters. Cells were incubated with $[^3]$H]substrates at 10 nM in the absence or presence of methylone at various concentrations. Specific uptake was expressed as a percentage of the control, and values represent the mean ± SEM, n=3. Control uptake in the absence of drugs was 4715 ± 182, 4961 ± 170, 13964 ± 1135, and 798 ± 114 dpm/well for DAT, NET, SERT and GAT, respectively.

Table 1. Effects of Methylone and Methamphetamine on the Uptake of Monoamines in CHO Cells Stably Expressing rat DAT, NET and SERT

| Transporter | IC50 ($\mu$M) | Methamphetamine |
|-------------|--------------|-----------------|
| DAT         | 2.84 ± 0.36  | 0.65 ± 0.06     |
| NET         | 0.48 ± 0.03  | 0.16 ± 0.00     |
| SERT        | 8.42 ± 1.01  | 27.62 ± 2.87    |

Values represent the mean ± SEM for three experiments each performed in triplicate.
Next, we analyzed the effect of methylone on uptake kinetically. Table 2 summarizes the effects on \([\text{3H}]\)substrates in comparison with those of methamphetamine. Methylone increased the \(K_m\) value without changing the \(V_{\text{max}}\) for the uptake of \([\text{3H}]\)NE, indicating competitive inhibition similar to methamphetamine (Table 2). On the other hand, it showed uncompetitive inhibition of \([\text{3H}]\)DA and \([\text{3H}]\)5-HT, tending to decrease the \(V_{\text{max}}\) while increasing the \(K_m\), as methamphetamine did.

### Effects of Methylone and Methamphetamine on the Reverse Transport of \([\text{3H}]\)substrates

To further characterize the effects of methylone on the monoamine transporters, we examined its influence on the reverse transport of \([\text{3H}]\)substrates through DAT, NET and SERT in comparison with methamphetamine, since unlike cocaine, methamphetamine induces the release of monoamines via a reversal of transport [13]. Methylone elicited the release of \([\text{3H}]\)DA, \([\text{3H}]\)NE and \([\text{3H}]\)5-HT from the cells expressing rDAT, rNET and rSERT, respectively, similar to methamphetamine (Fig. 2). In addition, the combination of methylone and methamphetamine did not cause a further increase in the release of \([\text{3H}]\)substrates.

### Cytotoxicity Elicited by Methylone and/or Methamphetamine

Initially, we examined the effect of methylone and methamphetamine on cell viability using a MTT-based WST-1 assay previously applied to Foxy [10]. However, we found no changes with methylone and/or methamphetamine at any concentrations tested (data not shown). Therefore, we used a LDH release assay to evaluate methylone’s toxicity.

| Table 2. Changes in the Transport Kinetics Induced by Methylone and Methamphetamine in CHO Cells Stably Expressing the Monoamine Transporters |
|-----------------|-----------------|
|                 | \(K_m\) (\(\mu M\)) | \(V_{\text{max}}\) (fmol/\(\mu g\) protein/min) |
| **DAT**         |                 |
| Control         | 1.73 ± 0.55     | 34.12 ± 7.64 |
| Methylone 5\(\mu M\) | 2.33 ± 0.67     | 26.68 ± 8.70 |
| Methamphetamine 1\(\mu M\) | 2.06 ± 0.83     | 24.18 ± 9.89 |
| **NET**         |                 |
| Control         | 0.25 ± 0.03     | 3.63 ± 0.31  |
| Methylone 0.5\(\mu M\) | 0.58 ± 0.10*    | 4.54 ± 1.01  |
| Methamphetamine 0.2\(\mu M\) | 0.71 ± 0.20     | 4.69 ± 0.49  |
| **SERT**        |                 |
| Control         | 0.27 ± 0.04     | 40.68 ± 7.23 |
| Methylone 10\(\mu M\) | 1.12 ± 0.25*    | 36.95 ± 5.68 |
| Methamphetamine 30\(\mu M\) | 0.86 ± 0.21*    | 31.41 ± 4.63 |

Values represent the mean ± SEM for three experiments each performed in triplicate. *\(P<0.05\) vs control.

**Fig. (2).** Effects of methylone and methamphetamine on the reverse transport of \([\text{3H}]\)substrates through the monoamine transporters. CHO cells stably expressing rDAT, rNET, or rSERT were preloaded with a \([\text{3H}]\)substrate at 20 nM for 30 min. They were then washed with KRH buffer, and incubated for 2min in fresh medium containing 100 \(\mu M\) methylone and/or 100 \(\mu M\) methamphetamine. Values represent the mean ± SEM, n=8-11, and are expressed as a percentage of the control (without drugs). *\(P<0.05\), **\(P<0.01\) vs control.
Fig. (3) shows the cytotoxicity of methylone and methamphetamine in CHO cells stably expressing rDAT, rNET and rSERT, together with mGAT1 as a control. Methylone did not induce the release of LDH from any cell line except that expressing SERT (Fig. 3). Furthermore, in combination with methamphetamine it had a significant increase in the release of LDH in the cells stably expressing the monoamine transporters but not in the control CHO cells or cells expressing GAT (Fig. 3).

**DISCUSSION**

The present study demonstrated that methylone acts as a non-selective inhibitor of the monoamine neurotransmitter transporters DAT, NET and SERT, with a rank order in terms of potencies of NET > DAT >> SERT. Kinetic analyses revealed the characteristics of the inhibition to resemble those by methamphetamine. In addition, methylone induced a reversal of transport similar to methamphetamine. Methamphetamine, like amphetamine, is transported by DAT and NET, and probably SERT [13]. The present study demonstrated that methylone had similar properties to methamphetamine not only in inhibiting the uptake by transporters but also in reversing the direction of transport, suggesting that it too is likely to be a transportable inhibitor. However, methylone itself was cytotoxic only at high concentrations, though in combination with methamphetamine it had a significant effect on cells expressing the monoamine transporters but not the control CHO cells or cells expressing GAT. These results suggest that the transport of methylone through monoamine transporters underlies the cytotoxicity.

The effectiveness of methylone and methamphetamine in inhibiting the uptake of substrates by monoamine transporters demonstrated here was well consistent with previous findings [5, 6]. Cozzi et al. [5] found that methylone inhibited DAT more than NET, while Nagai et al. [6] and ourselves observed a more potent effect on NET than DAT. On the other hand, Nagai et al. [6] reported that methylone inhibited DAT and SERT equally, while Cozzi et al. [5] and ourselves found the effect to be weaker at SERT than DAT. The discrepancy may be due to the different preparations or concentrations of labeled substrates used.

The concentrations of methylone in the brain at dosages at which the drug is abused, 100–200 mg [14], are unknown. Experiments with rats demonstrated the intraperitoneal administration of methylone at 5 mg/kg to be followed by a rapid increase in the plasma concentration ranging from 700 to 1500 ng/mL within 15 or 30 min [11]. These values seem compatible with those for MDMA [7]. Therefore, the present findings suggest that methylone may inhibit monoamine transporters in the CNS at concentrations relevant to its abuse.

The present study demonstrated cytotoxicity at high concentrations, as assessed from the amount of LDH released in
CHO cells. This effect was observed in cells expressing the monoamine transporters, especially those expressing SERT, but not cells expressing mGAT1, suggesting a relationship with the transport of methylene, although the affinity of the transporter for methylene does not explain the potency of methylene’s toxicity. In addition, the present study demonstrated that methylene and methamphetamine combined had a supra-additive effect on the release of LDH in CHO cells expressing monoamine transporters. The cytosolic accumulation of monoamines or methamphetamine may cause oxidative stress, resulting in cell death [15]. Therefore, one may assume that methylene modulates the toxic effects of other monoaminergic agents, such as methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA), through interaction at monoamine transporters. Recently, Shimizu et al. [14] reported a case study of a 27-year-old male who took methylene and 5-MeO-MIPT after ingesting a drug powder called pure methylene obtained via the internet, suggesting that substance-related disorders may be complicated by the combined use of psychoactive drugs. According to recent analyses, “ecstasy” and other designer drugs consist of mixtures of MDMA and other substances [16, 17]. Therefore, it is important to note their cytotoxicity when taken simultaneously. Further study is needed to clarify this issue.

In summary, we investigated the effects of methylene on monoamine transporters. The ability of methylene to inhibit transporter function, and damage cells heterologously expressing monoamine transporters, suggests that the transport of methylene underlies its cytotoxicity.

ACKNOWLEDGEMENTS

This study was supported in part by a Grant-in-aid for Scientific Research from the Ministry of Education, Culture, Science, Sports and Technology (SK), and Grant-in-Aid for health and Labor Science Research (Research on Pharmaceutical and Medical Safety) from the Ministry of Health, Labor and Welfare of Japan (IS).

REFERENCES

[1] Bossong, M.G.; Van Dijk, J.P.; Niesink, R.J.M. Methylene and mCPP, two new drugs of abuse? Addict. Biol., 2005, 10, 321-323.
[2] Dal Cason, T.A. The characterization of some 3,4-methylenedioxyamphetamine (MDCA) homologs. Forens. Sci. Int., 1997, 87, 9-53.
[3] Uchiyama, N.; Kikura-Hanajiri, R.; Kawahara, N.; Goda, Y. Analysis of designer drugs detected in the products purchased in fiscal year 2006. Yakugaku Zasshi, 2008, 128, 1499-1505.
[4] Dal Cason, T.A.; Young, R.; Glennon, R.A. Cathinone: an investigation of several N-alkyl and methylenedioxyl-substituted analogs. Pharmacol. Biochem. Behav., 1997, 58, 1109-1116.
[5] Cozzi, N.V.; Sievert, M.K.; Shulgin, A.T.; Jacob III, P.; Ruoho, A.E. Inhibition of plasma membrane transporters by β-ketoamphetamine. Eur. J. Pharmacol., 1999, 381, 63-69.
[6] Nagai, F.; Nonaka, R.; Satoh, K.; Kamimura, H. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur. J. Pharmacol., 2007, 559, 132-137.
[7] Baumann, M.H.; Wang, X.; Rothman, R.B. 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology, 2007, 189, 407-424.
[8] Fleckenstein, A.E.; Gibb, J.W.; Hanson, G.R. Differential effects on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur. J. Pharmacol., 2000, 406, 1-13.
[9] Nakagawa, Y.; Suzuki, T.; Tayama, S.; Ishii, H.; Ogata, A. Cytotoxic effects of 3,4-methylenedioxy-N-alkylamphetamines, MDMA and its analogues, on isolated rat hepatocytes. Arch. Toxicol., 2009, 83, 69-80.
[10] Sogawa, C.; Sogawa, N.; Tagawa, J.; Fujino, A.; Ohyama, K.; Asanuma, M.; Funada, M.; Kitayama, S. 5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter. Toxicol. Lett., 2007, 170, 75-82.
[11] Kikura-Hanajiri, R.; Kawamura, M.; Saisho, K.; Kodama, Y.; Goda, Y. The disposition into hair of new designer drugs; methylene, MBDB and methcatinone. J. Chromatogr. B, 2007, 855, 121-126.
[12] Kitayama, S.; Mitsuhasha, C.; Davis, S.; Wang, J.B.; Sato, T.; Morita, K.; Uhl, G.R.; Dohi, T. MPP+ toxicity and plasma membrane dopamine transporter: study using cell lines expressing the wild-type and mutant dopamine transporters. Biochim. Biophys. Acta, 1998, 1404, 305-313.
[13] Rudnick, G.; Clark, J. From synapse to vesicle: the reuptake and strage of biogenic amine neurotransmitters. Biochim. Biophys. Acta, 1993, 1144, 249-263.
[14] Shimizu, E.; Watanabe, H.; Kojima, T.; Hagiwara, H.; Fujisaki, M.; Miyatake, R.; Hashimoto, K.; Iyo, M. Combined intoxication with methylene and 5-MeO-MITP. Eur. J. Pharmacol., 2007, 559, 288-291.
[15] Ross, S.B. Pharmacological and toxicological exploitation of amine transporters. Trend. Pharmacol. Sci., 1987, 8, 227-231.
[16] Tanner-Smith, E.E. Pharmacological content of tablets sold as ‘ecstasy’: results from an online testing service. Drug Alcohol Depend., 2006, 83, 247-254.
[17] Teng, S.F.; Wu, S.C.; Liu, C.; Li, J.H.; Chien, C.S. Characteristics and trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005. Forens. Sci. Int., 2006, 161, 202-208.

Received: October 01, 2009 Revised: April 17, 2010 Accepted: May 26, 2010